Webinar - Final Guidances on Next Generation Sequencing-based Tests - May 24, 2018 - 05/23/2018 - 05/23/2018
- May 24, 2018
- May 24, 2018
On Thursday, May 24, the FDA hosted a webinar about two finalized guidances designed to enhance collaboration among researchers, and drive the efficient development of novel next generation sequencing (NGS) based tests. The guidances outline innovative regulatory approaches for the oversight of medical technologies that play an important role in the continued advancement of individualized, genetic-based medicine.
The first guidance, “Use of Public Human Genetic Variant Databases to Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics,” describes an approach where test developers may rely on clinical evidence from FDA-recognized public databases to support clinical claims for their tests and provide assurance of the accurate clinical evaluation of genomic test results. Using FDA-recognized databases will provide test developers with an efficient path for marketing clearance or approval of a new test.
The second guidance, “Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing (NGS)–Based In Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected Germline Diseases,” provides recommendations for designing, developing, and validating NGS-based tests used to diagnose individuals with suspected genetic diseases. It clarifies how the FDA evaluates premarket submissions to determine a test’s analytical validity, including how well it detects the presence or absence of a particular genomic change.
A transcript, recording and slides will be available at: http://www.fda.gov/CDRHWebinar after the webinar. The slide presentation will also be available at this site on the morning of the webinar.
As always, we appreciate your feedback. Following the conclusion of the webinar, please complete a short survey about your FDA medical device webinar experience. The survey can be found at www.fda.gov/CDRHWebinar immediately following the conclusion of the live webinar.
NOTE: The FDA does not provide Continuing Education Credits (CEU) or Certificates of Attendance.
If you have any questions, please contact the Division of Industry and Consumer Education (DICE) in the Center for Devices and Radiological Health (CDRH) at 1-800-638-2014, 301-796-7100 or email@example.com.